StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
301206.SZ$25.02-2.07%
Fair $25.02+0.0%

301206.SZ

Shandong Sanyuan Biotechnology Co.,Ltd.

Consumer Defensive / ConfectionersShenzhen

$25.02

-0.53 (-2.07%)

Fairly Valued+0.0%Fair Value $25.02Fund rank 23/100 · Data gapFallback financials|
SA 19/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-155.4M · quality 53.7/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 28/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

19/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists. ROE is 2.2%, below the 5% threshold
Thesis & Journal · 301206.SZLocal privado en este navegador · Shandong Sanyuan Biotechnology Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5.1B

P/E

53.2x

↑

EV/EBITDA

44.8x

↑

ROE

2.2%

↓

Gross Margin

16.1%

↓

Debt/Equity

N/A

•
52-Week Range$25
$25$35

TradingView lightweight chart

301206.SZ price, volumen y niveles de valoración

Último $25.02Periodo -70.7%
Fair value: $25.02

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-1.3%

FCF CAGR

—

FCF margin

-27.1%

FCF / Net income

-1.93x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $649.5M · net income $91.4M · FCF $-176.3M

2022-FY → 2025-FY

Gross margin

16.1%+2.1% pts

Operating margin

4.6%-2.5% pts

Net margin

14.1%-10.2% pts

FCF margin

-27.1%-3.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$649.5M$649.5M$712.9M$499.5M$674.9M
Net Income$91.4M$91.4M$105.0M$56.0M$163.7M
EBITDA$103.7M$103.7M$76.2M$1.6M$222.7M
EPS0.460.460.520.280.82
Gross Margin16.1%16.1%11.1%3.1%14.1%
Operating Margin4.6%4.6%1.4%-11.6%7.2%
Net Margin14.1%14.1%14.7%11.2%24.3%
Balance Sheet
Current Ratio10.5610.56———
Cash Flow
Free Cash Flow$-176.3M$-176.3M$-155.4M$-65.7M$-158.4M
Returns
ROE2.2%2.2%2.3%1.2%3.5%
Valuation
P/E53.2353.2347.6999.7546.44
EV/EBITDA44.8344.8363.553435.6331.94
P/B1.171.171.111.231.65
Growth & Yield
Revenue Growth-8.9%-8.9%42.7%-26.0%—
EPS Growth-11.5%-11.5%85.7%-65.9%—
Dividend Yield6.9%6.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

69.0%

muy exigente

EPS terminal req.

$2.22

Spread vs growth

-80.5%

5Y implied EPS CAGR

42.3%

muy exigente

EPS terminal req.

$2.69

Spread vs growth

-53.9%

10Y implied EPS CAGR

25.1%

muy exigente

EPS terminal req.

$4.33

Spread vs growth

-36.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -11.4%

Total return

-11.4%

Start / end P/E

58.8x → 54.4x

EPS bridge

0.52 → 0.46

Residual

+0.9%

EPS growth-11.5%
Multiple rerating-7.6%
Dividend+6.9%
Residual / FX / buybacks / cross-term+0.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.